dc.description.sponsorship | D.H. Whittam, E.Gibbons, V. Karthikeayan, R. Kneen, S. Chandratre, J. de Seze, K. Deiva, R.Q. Hintzen, I. Kleiter, K. Rostasy, P. Huppke, F. Paul, A.K. Pröbstel, M.P. Amato, M. Nosadini, M.M. Mancardi, Z. Illes, A. Siva, G. Akman-Demir, L. Pandit, M. Apiwattankul, J.Y. Hor, S. Viswanathan, W. Qiu, H.J. Kim, I. Nakashima, R.C. Dale, M. Boggild, S. Broadley, M.A. Lana-Peixoto, P. Cabre, B.G. Weinshenker, B. Greenberg, M. Matiello, E.C. Klawiter, J.L. Bennett, A.I. Wallach, I. Kister, B.L. Banwell, D. Pohl, M.Levy, M.I. Leite, T. Solomon: nothing to disclose. O. Ciccarelli is a consultant for Roche, Novartis, Teva, Biogen and Merck. B Wildemann has received research grants and/or honoria from Merck Serono, Biogen, Teva, Novartis, Sanofi Genzyme, Bayer Healthcare, and research grants from Bundesministerium für Bildung und Forschung, Deutsche Forschungsgemeinschaft, Dietmar Hopp Foundation and the Klaus Tschira Foundation. S. Jarius’s work was indirectly supported by research grants from Dietmar Hopp Stiftung and from Merck Serono. I.Kleiter has received speaker honoraria and travel funding from Bayer, Biogen, Novartis, Merck, Sanofi Genzyme, Roche; speaker honoraria from Mylan; travel funding from the Guthy-Jackson Charitable Foundation; consulted for Alexion, Bayer, Biogen, Celgene, Chugai, IQVIA, Novartis, Merck, Roche; and research support from Chugai, Diamed. B. Hemmer has served on scientific advisory boards for F. Hoffmann-La Roche Ltd, Novartis, and Bayer AG; he has served as DMSC member for AllergyCare and TG Therapeutics; he or his institution have received speaker honoraria from Medimmune, Novartis, Desitin, and F. Hoffmann-La Roche Ltd; his institution has received research support from Chugai Pharmaceuticals; holds part of two patents; one for the detection of antibodies and T cells against KIR4.1 in a subpopulation of MS patients and one for genetic determinants of neutralizing antibodies to interferon ?. O. Aktas reports grants from the German Research Foundation (DFG) and the German Ministry of Education and Research (BMBF), grants and personal fees from Bayer HealthCare, Biogen, Genzyme, Novartis, Teva and Viela Bio, and personal fees from Almirall, MedImmune, Merck Serono and Roche. G. Arrambide has received compensation for consulting services or participation in advisory boards from Sanofi, Merck, and Roche; research support from Novartis; travel expenses for scientific meetings from Novartis, Roche, Stendhal, and ECTRIMS; and speaking honoraria from Sanofi, Merck, and Novartis. M. Tintore has received compensation for consulting services and speaking honoraria from Almirall, Bayer Schering Pharma, Biogen-Idec, Genzyme, Merck-Serono, Novartis, Roche, Sanofi-Aventis, and Teva Pharmaceuticals. MT is co-editor of Multiple Sclerosis Journal-ETC. M. Capobianco received personal honoraria for speaking at meeting or participating in advisory boards from Biogen, Merck, Novartis, Roche, Sanofi, Teva. A. Altintas received travel grants and/or speaker honoraria from Merck, Generica and Novartis. H.J. Kim received research support from the Ministry of Science and ICT, Genzyme, Merck Serono, Teva-Handok, and UCB; received consultancy/speaker fees from Celltrion, Eisai, HanAll BioPharma, MedImmune, Merck Serono, Novartis, Sanofi Genzyme, Teva-Handok, and UCB; serves on a steering committee for MedImmune/VielaBio; is a co-editor for the Multiple Sclerosis Journal—Experimental, Translational, and Clinical, and an associated editor for the Journal of Clinical Neurology. K. Fujihara received consultancy/speaker fees: Alexion Pharmaceuticals, Chugai, Asahi Kasei Medical, Biogen, Eisai, Mitsubishi-Tanabe Pharma, Nihon, Novartis Pharmaceuticals, ONO Pharmaceutical, Takeda, and Teijin. S. Ramanathan has received an Early Career Fellowship from the National Health and Medical Research Council (Australia). D.K. Sato has received a Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (KAKENHI 15K19472); research support from CNPq/Brasil (425331/2016-4), FAPERGS/MS/CNPq/SESRS (17/2551-0001391-3) PPSUS/Brazil, TEVA (research grant for EMOCEMP Investigator Initiated Study), and Euroimmun AG (Neuroimmunological Complications associated with Arboviruses); and speaker honoraria from Biogen, Novartis, Genzyme, TEVA, Merck-Serono, Roche, and Bayer and has participated in advisory boards for Shire, Roche, TEVA, Merck-Serono and Quest/Athena Diagnostics. S. Tenembaum serves as a non-remunerated editorial board member of Neurology: Neuroimmunology & Neuroinflammation. She has received speaker and consulting fees from Biogen-Idec Argentina, Merck Serono LATAM, Genzyme-Sanofi, Novartis, and Teva Neuroscience during the last 3 years. D.M. Wingerchuk received grant support paid to Mayo Clinic from Alexion and TerumoBCT, consultant fees from MedImmune, Celgene, Novartis, and ONO Pharmaceuticals. A. Traboulsee: has received research funding from Chugai, Roche, and Sanofi Genzyme; received honoraria or travel support from Consortium of MS Centers, MS Society of Canada, Biogen, Teva, Roche, Merck/EMD Serono, Sanofi Genzyme, Chugai. J. Palace is partly funded by highly specialised services to run a national congenital myasthenia service and a neuromyelitis optica service. She has received support for scientific meetings and honorariums for advisory work from Merck Serono, Biogen Idec, Novartis, Teva, Chugai Pharma and Bayer Schering, Alexion, Roche, Genzyme, MedImmune, EuroImmun, MedDay, Abide ARGENX, UCB and Viela Bio and grants from Merck Serono, Novartis, Biogen Idec, Teva, Abide, MedImmune, Bayer Schering, Genzyme, Chugai and Alexion. She has received grants from the MS society, Guthrie Jackson Foundation, NIHR, Oxford Health Services Research Committee, EDEN, MRC, GMSI, John Fell and Myaware for research studies. R. Marignier serves on the scientific advisory board for Novartis and Medimmune; received speaker honoraria and travel funding from Novartis, Biogen, Teva, Sanofi-Aventis/Genzyme, Merck. M. Lim has received consultation fees from CSL Behring; received travel grants from Merck Serono; and was awarded educational grants to organize meetings by Novartis, Biogen Idec, Merck Serono and Bayer. S. Huda has received research support from the Neuromyelitis Optica UK charity. A. Jacob served on the scientific advisory board for Shire Pharmaceuticals; received travel funding and/or speaker honoraria from Biogen Idec, Shire, and Terumo BCT; consulted for Shire Pharmaceuticals; and received research support from Biogen, Alexion Pharmaceuticals, NHS, and University of Liverpool. | en_US |
dc.department-temp | Whittam, D.H., Department of Neurology, the Walton Centre NHS Foundation Trust, Liverpool, United Kingdom; Karthikeayan, V., Department of Neurology, the Walton Centre NHS Foundation Trust, Liverpool, United Kingdom; Gibbons, E., Department of Neurology, the Walton Centre NHS Foundation Trust, Liverpool, United Kingdom; Kneen, R., Department of Paediatric Neurology, Alder Hey Children’s Hospital, Liverpool, United Kingdom; Chandratre, S., Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, United Kingdom; Ciccarelli, O., Queen Square Multiple Sclerosis Centre, UCL Institute of Neurology, London, United Kingdom; Hacohen, Y., Queen Square Multiple Sclerosis Centre, UCL Institute of Neurology, London, United Kingdom, Department of Paediatric Neurology, Great O | en_US |